Maralixibat 9.5mg/ml oral solution sugar free
NHS hospitals in England used £17,719,910 of indicative cost of Maralixibat 9.5mg/ml oral solution sugar free in the 12 months to March 2026, about 0.1% of all hospital medicines spend. That is up 8.0% on the previous 12 months.
Indicative cost · 12 months
Quantity (VMP units) · 12 months
Share of hospital medicines spend
Figure 1. Maralixibat 9.5mg/ml oral solution sugar free: NHS hospital indicative cost by month (£ millions)
Source: NHSBSA Secondary Care Medicines Data, to March 2026
Cost is indicative — actual hospital medicine prices are commercially confidential, so these figures are estimated from list prices. See methodology.
NHS trusts using Maralixibat 9.5mg/ml oral solution sugar free most
By indicative cost over the 12 months to March 2026.
| NHS trust | Indicative cost (12 months) |
|---|---|
| King's College Hpl Nhs Foundation Trust | £8,881,940 |
| Univ Hpl B/Ham Nhs Foundation Trust | £4,704,790 |
| Royal Free London Nhs Foundation Trust | £2,550,260 |
| Imperial College Healthcare Nhs Trust | £307,790 |
| Birmingham Womans & Childrens Nhs Ft | £175,880 |
| The Newcastle Upon Tyne Hpl Nhs Found Tr | £131,910 |
The primary-care picture
No confident match to a community-dispensed medicine was found for this product, so no primary-care comparison is shown. SCMD products are recorded at product level, which does not always map cleanly to a BNF substance.